Corona Remedies IPO gets all the love, Wakefit left waiting

Business Dec 10, 2025

The IPOs for Corona Remedies and Wakefit Innovations just wrapped up, but investor excitement couldn't have been more different.
Corona Remedies was a clear favorite, getting oversubscribed by over 31 times, while Wakefit's IPO barely reached 60% of its target by the close.

How investors responded

Corona Remedies saw huge demand from everyone—especially non-institutional investors, who subscribed over 100 times their quota. Retail and institutional buyers also showed strong interest.
The company raised ₹655 crore with shares priced between ₹1,008-₹1,062.
Meanwhile, Wakefit's IPO (priced at ₹185-₹195) got some attention from retail investors but struggled to attract big players.
Both companies are set to list on December 15.